Medication
Salofalk
DIN 02112809 · Abbvie Corporation
What it is
- Active ingredients
- Mesalazine — 4 g
- Form and route
- Suspension · Rectal
- Schedule
- PRESCRIPTION
- Authorised since
- 1995-12-31
Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.
Products with the same active ingredient
No other medication authorised in Canada shares this active ingredient.
Health Canada groups products by their active ingredients. No other marketed product shares this one’s group, which usually means it is still the only authorised version — not that alternatives were hidden or missed.
Watch this medication
Ontario Drug Benefit coverage
As of 31 July 2026General benefit Part III-A
Ontario lists this product as a general benefit under the Ontario Drug Benefit program — Part III-A of the Formulary/CDI. For someone eligible for ODB, it is covered without a drug-specific approval.
- What ODB pays per unit
- $10.0389
This is what the Ontario Drug Benefit program reimburses a pharmacy for one unit, as of 31 July 2026. A deductible and a co-payment sit on top of it and differ by program — ODB, the Trillium Drug Program and the seniors co-payment each work differently — so it is not the figure anyone is charged at a counter. It also says nothing about private, workplace or federal coverage.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
How it is classified
- Anatomical main group
- Alimentary tract and metabolism
- ATC code
- A07EC02
The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of A07EC02, see the WHO ATC/DDD Index.
Recalls and safety alerts
As of 12 August 2026Health Canada has published a recall or safety alert naming this product. Read it on Health Canada’s own site, and speak to a pharmacist before changing anything about how you take this medication.
SALOFALK 500mg: tablets may show black spots due to the oxidation of the active ingredient.
Health Canada says: Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns. Contact the recalling firm if you have any questions about the recall.Report any health product related side effects to Health Canada.Report any other health product safety complaints to Health Canada.
Matched on the product name at the start of the notice.
This list may be incomplete. Health Canada’s recalls data carries no DIN, so notices are matched on wording alone. Search Health Canada recalls for Salofalk → How RxMonitor matches recalls, and how often it fails
Source: Health Canada — Recalls and Safety Alerts. Data current as of 2026-08-12. Matched on product name, not on DIN — the feed carries none.